The United States of America As Represented by the Secretary of

The United States of America As Represented by the Department of Health

Anne Hosmalin

Jay A Berzofsky

Bernard Moss

Ronald N Germain

Gene M Shearer

James L Cornette

Mario S Clerici

Hanah Margalit

Paula M Hale

Charles D Pendleton

John L Spouge

The subject invention relates to a peptide having the amino acid sequence Glu-Ile-Cys-Thr-Glu-Met-Glu-Lys-Glu-Gly-Lys-Ile-Ser-Lys-Ile-Gly-Pro or portions thereof. This peptide is derived from, or based upon, a region of a relatively conserved epitope of HIV-1 reverse transcriptase. The peptide may be utilized in the treatment of patients having human immunodeficiency virus or in the prevention of infection of those individuals who have been exposed to the disease, yet have not become sero-positive. The preparation containing the peptide may be administered either subcutaneously, intramuscularly or intravenously.

Peptides stimulating cytotoxic T cells immune to HIV RT

The invention relates to peptide antigens which stimulate helper T lympocytes which specifically recognize HIV envelope protein, thereby enhancing antibody production and cytotoxic T cells to inhibit expression of an infection caused by HIV virus.

Synthetic vaccine against AIDS virus

Growing community of inventors

Bethesda, MD, United States of America

Anne Hosmalin